Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP's narrower antigen base is less effective against current pathogen strains.
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Pfizer Inc and Johnson & Johnson, etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
By Company
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
By Type
Immune DTaP Vaccine
Therapy DTaP Vaccine
By Application
Adult
Pediatric
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
Table of Content
1 Report Overview
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Definition
1.2 Market by Type
1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Immune DTaP Vaccine
1.2.3 Therapy DTaP Vaccine
1.3 Market Segment by Application
1.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Adult
1.3.3 Pediatric
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales
2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region
2.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2018-2023)
2.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2024-2034)
2.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Region
2.6.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Region (2018-2023)
2.6.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Manufacturers
3.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in 2024
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2018-2023)
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue in 2024
3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type
4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Revenue by Type (2018-2023)
4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type
4.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2018-2023)
4.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application
5.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application
5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historical Revenue by Application (2018-2023)
5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application
5.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2018-2023)
5.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company
6.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023)
6.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023)
6.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
6.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2034)
6.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
6.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2034)
6.4 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
6.4.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2034)
6.4.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company
7.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023)
7.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023)
7.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
7.2.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2034)
7.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
7.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2034)
7.4 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
7.4.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company
8.1.1 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023)
8.1.2 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023)
8.2 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
8.2.1 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2034)
8.3 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
8.3.1 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company
9.1.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023)
9.1.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023)
9.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
9.2.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2034)
9.3 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
9.3.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2034)
9.4 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
9.4.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Sanofi Pasteur
11.1.1 Sanofi Pasteur Company Information
11.1.2 Sanofi Pasteur Overview
11.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.1.5 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.1.6 Sanofi Pasteur Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.2.5 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.2.6 GlaxoSmithKline Recent Developments
11.3 Protein Sciences Corporation
11.3.1 Protein Sciences Corporation Company Information
11.3.2 Protein Sciences Corporation Overview
11.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.3.5 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.3.6 Protein Sciences Corporation Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Information
11.4.2 Novartis AG Overview
11.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.4.5 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.4.6 Novartis AG Recent Developments
11.5 Seqirus
11.5.1 Seqirus Company Information
11.5.2 Seqirus Overview
11.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.5.5 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.5.6 Seqirus Recent Developments
11.6 Merck Sharp & Dohme Corp
11.6.1 Merck Sharp & Dohme Corp Company Information
11.6.2 Merck Sharp & Dohme Corp Overview
11.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.6.5 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.6.6 Merck Sharp & Dohme Corp Recent Developments
11.7 Astellas Pharma US
11.7.1 Astellas Pharma US Company Information
11.7.2 Astellas Pharma US Overview
11.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.7.5 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.7.6 Astellas Pharma US Recent Developments
11.8 Pfizer Inc
11.8.1 Pfizer Inc Company Information
11.8.2 Pfizer Inc Overview
11.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.8.5 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.8.6 Pfizer Inc Recent Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Information
11.9.2 Johnson & Johnson Overview
11.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.9.5 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.9.6 Johnson & Johnson Recent Developments
11.10 Lanzhou Institute of Biological Products Co., Ltd
11.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
11.10.2 Lanzhou Institute of Biological Products Co., Ltd Overview
11.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.10.5 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
11.10.6 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
11.11 AstraZeneca
11.11.1 AstraZeneca Company Information
11.11.2 AstraZeneca Overview
11.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.11.5 AstraZeneca Recent Developments
11.12 Emergent BioSolutions Inc
11.12.1 Emergent BioSolutions Inc Company Information
11.12.2 Emergent BioSolutions Inc Overview
11.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products and Services
11.12.5 Emergent BioSolutions Inc Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain Analysis
12.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
12.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Marketing
12.4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels
12.4.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
12.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
13 Market Dynamics
13.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
13.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
13.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
13.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Figure
List of Tables
Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Immune DTaP Vaccine
Table 3. Major Manufacturers of Therapy DTaP Vaccine
Table 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2018-2023)
Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Doses)
Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2018-2023) & (K Doses)
Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2018-2023)
Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2024-2034) & (K Doses)
Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Manufacturers (2018-2023) & (K Doses)
Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Manufacturers (2018-2023)
Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers (2018-2023)
Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Manufacturers 2018-2023 (USD/Dose)
Table 20. Global Key Players of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Industry Ranking, 2021 VS 2024
Table 21. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2024)
Table 23. Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Type (2018-2023)
Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Type (2024-2034)
Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2018-2023)
Table 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2024-2034)
Table 35. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2018-2023) & (USD/Dose)
Table 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Type (2024-2034) & (USD/Dose)
Table 37. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 38. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 39. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Application (2018-2023)
Table 40. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Application (2024-2034)
Table 41. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2018-2023)
Table 44. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2024-2034)
Table 45. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2018-2023) & (USD/Dose)
Table 46. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price Forecast by Application (2024-2034) & (USD/Dose)
Table 47. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 48. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 49. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 50. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 51. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 52. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 54. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 55. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 56. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 58. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 59. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2018-2023) & (K Doses)
Table 61. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 62. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 63. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 64. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 65. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 66. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 67. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 69. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 70. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 71. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 73. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 74. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2018-2023) & (K Doses)
Table 76. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 77. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 78. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 79. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 80. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 81. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 82. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 84. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 85. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 86. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 88. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 89. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 90. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 91. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 92. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 94. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 95. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 96. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 98. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 99. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Region (2018-2023) & (K Doses)
Table 101. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Region (2024-2034) & (K Doses)
Table 102. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 103. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 105. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 106. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 109. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 110. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2018-2023) & (K Doses)
Table 116. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 117. Sanofi Pasteur Company Information
Table 118. Sanofi Pasteur Description and Overview
Table 119. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 120. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 121. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 122. Sanofi Pasteur Recent Developments
Table 123. GlaxoSmithKline Company Information
Table 124. GlaxoSmithKline Description and Overview
Table 125. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 126. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 127. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 128. GlaxoSmithKline Recent Developments
Table 129. Protein Sciences Corporation Company Information
Table 130. Protein Sciences Corporation Description and Overview
Table 131. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 132. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 133. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 134. Protein Sciences Corporation Recent Developments
Table 135. Novartis AG Company Information
Table 136. Novartis AG Description and Overview
Table 137. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 138. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 139. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 140. Novartis AG Recent Developments
Table 141. Seqirus Company Information
Table 142. Seqirus Description and Overview
Table 143. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 144. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 145. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 146. Seqirus Recent Developments
Table 147. Merck Sharp & Dohme Corp Company Information
Table 148. Merck Sharp & Dohme Corp Description and Overview
Table 149. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 150. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 151. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 152. Merck Sharp & Dohme Corp Recent Developments
Table 153. Astellas Pharma US Company Information
Table 154. Astellas Pharma US Description and Overview
Table 155. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 156. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 157. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 158. Astellas Pharma US Recent Developments
Table 159. Pfizer Inc Company Information
Table 160. Pfizer Inc Description and Overview
Table 161. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 162. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 163. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 164. Pfizer Inc Recent Developments
Table 165. Johnson & Johnson Company Information
Table 166. Johnson & Johnson Description and Overview
Table 167. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 168. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 169. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 170. Johnson & Johnson Recent Developments
Table 171. Lanzhou Institute of Biological Products Co., Ltd Company Information
Table 172. Lanzhou Institute of Biological Products Co., Ltd Description and Overview
Table 173. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 174. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 175. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine SWOT Analysis
Table 176. Lanzhou Institute of Biological Products Co., Ltd Recent Developments
Table 177. AstraZeneca Company Information
Table 178. AstraZeneca Description and Overview
Table 179. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 180. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 181. AstraZeneca Recent Developments
Table 182. Emergent BioSolutions Inc Company Information
Table 183. Emergent BioSolutions Inc Description and Overview
Table 184. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 185. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 186. Emergent BioSolutions Inc Recent Developments
Table 187. Key Raw Materials Lists
Table 188. Raw Materials Key Suppliers Lists
Table 189. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
Table 190. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List
Table 191. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Trends
Table 192. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
Table 193. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
Table 194. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
Table 195. Research Programs/Design for This Report
Table 196. Key Data Information from Secondary Sources
Table 197. Key Data Information from Primary Sources
List of Figures
Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Picture
Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Type in 2024 & 2034
Figure 4. Immune DTaP Vaccine Product Picture
Figure 5. Therapy DTaP Vaccine Product Picture
Figure 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Application in 2024 & 2034
Figure 8. Adult
Figure 9. Pediatric
Figure 10. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Report Years Considered
Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2018-2034 (US$ Million)
Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity 2018-2034 (K Doses)
Figure 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Region (2018-2023)
Figure 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 17. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 18. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 20. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 22. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 24. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 26. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity in 2024
Figure 28. The Top 10 and Top 5 Players Market Share by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue in 2024
Figure 29. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2018-2034)
Figure 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2018-2034)
Figure 34. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company in 2024
Figure 35. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Company in 2024
Figure 36. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 37. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2018-2034)
Figure 38. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 39. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2018-2034)
Figure 40. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2018-2034)
Figure 41. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Country (2018-2034)
Figure 42. U.S. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Company in 2024
Figure 45. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company in 2024
Figure 46. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 47. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2018-2034)
Figure 48. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 49. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2018-2034)
Figure 50. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2018-2034)
Figure 51. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Country (2018-2034)
Figure 52. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 53. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 54. U.K. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Company in 2024
Figure 58. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company in 2024
Figure 59. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 60. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2018-2034)
Figure 61. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 62. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2018-2034)
Figure 63. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Company in 2024
Figure 64. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company in 2024
Figure 65. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 66. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2018-2034)
Figure 67. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 68. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2018-2034)
Figure 69. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Region (2018-2034)
Figure 70. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Share by Region (2018-2034)
Figure 71. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 72. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 73. China Taiwan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 74. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Company in 2024
Figure 77. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company in 2024
Figure 78. Middle East, Africa and Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 79. Middle East, Africa and Latin America Diphtheria, Tetanus, a
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices